GlassScriptPhysician profile
Owen W Roberts
NPI 1629179858
$2,138.50
in general payments reported to CMS, 2019-2025
23 companies · $1,912 in 2025
The $1,912 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $173 · 2024: $42.11 · 2025: $1,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $282.34 | 2022-2025 | |
| Janssen Biotech, INC. | $236.19 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Incyte Corporation | $177.97 | 2025 | Jakafi, Zynyz, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $150.91 | 2024-2025 | Tagrisso, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $150.85 | 2022-2025 | Opdivo, Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $148.26 | 2025 | Keytruda, Lynparza, Lenvima |
| Lilly USA, LLC | $105.78 | 2025 | Jaypirca, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $104.82 | 2025 | |
| Daiichi Sankyo INC. | $99.51 | 2025 | Datroway, Enhertu |
| Novartis Pharmaceuticals Corporation | $97.91 | 2022-2025 | |
| Progenics Pharmaceuticals, INC. | $96.86 | 2022 | |
| Abbvie INC. | $87.75 | 2025 | |
| Celgene Corporation | $86.36 | 2025 | Reblozyl |
| Servier Pharmaceuticals LLC | $69.90 | 2025 | |
| Caris Mpi, INC. | $55.50 | 2025 | Mi Cancer Seek |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $37.55 | 2025 | Brukinsa |
| Glaxosmithkline, LLC. | $36.23 | 2025 | Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $34.51 | 2025 | Ninlaro |
| Jazz Pharmaceuticals INC. | $20.29 | 2025 | |
| Pharmaessentia USA Corporation | $17.64 | 2025 | Besremi |
| Puma Biotechnology, INC. | $16.26 | 2025 | |
| Genzyme Corporation | $13.19 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Owen Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.